XML 47 R29.htm IDEA: XBRL DOCUMENT
v3.22.1

Note 3 - Research and Collaboration Agreements, Sublicense Agreements and Investments in Privately Held Companies (Details Textual) |  |  | 1 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 24, 2020 | Jun. 30, 2017 USD ($) | Jun. 30, 2017 EUR (€) | Aug. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | Dec. 16, 2021 USD ($) | Dec. 16, 2021 EUR (€) | Jul. 26, 2021 | Jul. 08, 2021 shares | Dec. 01, 2020 | Apr. 26, 2019
Upfront Payment Payable |  |  |  |  |  |  | $ 500,000 |  |  |  |  |
Research and Development Expense, Related Party |  |  |  |  | $ 0 |  |  |  |  |  |  |
Number of Performance Obligations |  |  |  |  |  |  | 2 | 2 |  |  |  |
Cost of Goods and Services Sold, Total |  |  |  |  | 1,944,438 | $ 1,424,931 |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Current, Total |  |  |  |  | 277,831 | 294,199 |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement |  | $ 1,100,000 | € 1,000,000.0 |  |  |  |  |  |  |  |  |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from Sales of Business, Affiliate and Productive Assets |  |  |  | $ 1,600,000 | 1,600,000 |  |  |  |  |  |  |
Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Payment for Research and Development Agreement | € |  |  | € 1 |  |  |  |  |  |  |  |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |
Sale of Stock, Percentage of Ownership after Transaction | 2.50% |  |  |  |  |  |  |  |  |  |  |
Equity Securities without Readily Determinable Fair Value, Amount |  |  |  |  |  | 284,709 |  |  |  |  |  |
Novovet [Member] |  |  |  |  |  |  |  |  |  |  |  |
Equity Method Investment, Ownership Percentage |  |  |  |  |  |  |  |  |  |  |  | 20.00%
Unbilled Revenues [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Current, Total |  |  |  |  | 176,656 | $ 163,667 |  |  |  |  |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |
Investment Owned, Balance, Shares (in shares) | shares |  |  |  |  |  |  |  |  |  | 129,661 |  |
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |  |  |  |  |  |  |  |  |  | 0.37% |  |
Alphazyme [Member] |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  |  |  | 1.99% |
BDI Holdings [Member] |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  | 16.10% |  |  |
BDI Holdings [Member] | Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 16.10% | 16.10% |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Minimum Obligation For Research and Development |  | $ 936,000 |  |  |  |  |  |  |  |  |  |
VLPBio Member |  |  |  |  |  |  |  |  |  |  |  |
Ownership Percentage |  |  |  |  |  |  |  |  | 3.30% |  |  |
VLPBio Member | Research Services Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement, Equity Interest Acquired |  | 3.30% | 3.30% |  |  |  |  |  |  |  |  |
Janssen Pharmaceutical Companies [Member] |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable Upfront Payment, Received |  |  |  |  |  |  | $ 500,000 |  |  |  |  |
Deferred License Revenue |  |  |  |  | 500,000 |  |  |  |  |  |  |
ID Biologics Inc [Member] |  |  |  |  |  |  |  |  |  |  |  |
Cost of Goods and Services Sold, Total |  |  |  |  | 194,000 |  |  |  |  |  |  |
ID Biologics Inc [Member] | Unbilled Revenues [Member] |  |  |  |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss, Current, Total |  |  |  |  | $ 27,000 |  |  |  |  |  |  |
Research and Development [Member] | Janssen Pharmaceutical Companies [Member] |  |  |  |  |  |  |  |  |  |  |  |
Contract with Customer, Asset, after Allowance for Credit Loss, Total | € |  |  |  |  |  |  |  | € 1,600,000 |  |  |  |

X
- Definition Represents equity interest acquired for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementEquityInterestAcquired
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents minimum obligation for research and development for collaborative agreement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents payment for research and development agreement for collaborate arrangement. + References No definition available. + Details
Name: | dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents deferred license revenue. + References No definition available. + Details
Name: | dyai_DeferredLicenseRevenue
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents ownership percentage by noncontrolling owners for noncontrolling interest. + References No definition available. + Details
Name: | dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents non-refundable upfront payment, received. + References No definition available. + Details
Name: | dyai_NonrefundableUpfrontPaymentReceived
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents number of performance obligations. + References No definition available. + Details
Name: | dyai_NumberOfPerformanceObligations
Namespace Prefix: | dyai_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of ownership. + References No definition available. + Details
Name: | dyai_OwnershipPercentage
Namespace Prefix: | dyai_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the amount of related-party research and development expense recognized during the period. + References No definition available. + Details
Name: | dyai_ResearchAndDevelopmentExpenseRelatedParty
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents upfront payment payable. + References No definition available. + Details
Name: | dyai_UpfrontPaymentPayable
Namespace Prefix: | dyai_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044 + Details
Name: | us-gaap_ContractWithCustomerAssetNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Balance held at close of period in number of shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 210 -Section 50 -Paragraph 6 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 320 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -URI http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate cash proceeds received from a combination of transactions in which noncurrent assets are sold, which may include the sale of a business, an investment in an affiliate (including an equity method investee), property, plant and equipment and intangible assets. Excludes sales of trading, available-for-sale, and held-to-maturity securities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dyai_ResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=dyai_NovovetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_AlphazymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_BDIHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=dyai_VLPBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_JanssenPharmaceuticalCompaniesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dyai_IDBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=dyai_ResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |